Bank of New York Mellon Corp Makes New Investment in DENTSPLY SIRONA Inc. $XRAY

Key Points

• Bank of New York Mellon acquired 1.55 million DENTSPLY SIRONA shares worth approximately $16.4 million, representing 0.77% of the company; institutional investors collectively own 95.7% of the stock.
• DENTSPLY SIRONA beat quarterly earnings expectations with $0.52 EPS versus the $0.35 consensus and $898 million in revenue, though revenue declined 4.1% year over year and the company reported a negative net margin.
• Analysts maintain a mixed outlook, with the stock carrying an average “Hold” rating and a $13.54 target price versus its recent $11.17 share price; insiders have also purchased 35,160 shares over the past 90 days.

Bank of New York Mellon Corp bought a new position in shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Free Report) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 1,546,449 shares of the medical instruments supplier's stock, valued at approximately $16,408,000. Bank of New York Mellon Corp owned 0.77% of DENTSPLY SIRONA as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in DENTSPLY SIRONA in the first quarter worth $26,000. Goldman Sachs Group Inc. boosted its holdings in shares of DENTSPLY SIRONA by 827.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,434,925 shares of the medical instruments supplier's stock valued at $36,378,000 after buying an additional 2,172,343 shares in the last quarter. Empowered Funds LLC boosted its holdings in shares of DENTSPLY SIRONA by 8.8% during the 1st quarter. Empowered Funds LLC now owns 16,324 shares of the medical instruments supplier's stock valued at $244,000 after buying an additional 1,320 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of DENTSPLY SIRONA by 7.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 593,021 shares of the medical instruments supplier's stock worth $8,860,000 after buying an additional 41,579 shares during the period. Finally, Focus Partners Wealth increased its stake in shares of DENTSPLY SIRONA by 59.1% in the 1st quarter. Focus Partners Wealth now owns 25,181 shares of the medical instruments supplier's stock worth $376,000 after acquiring an additional 9,355 shares in the last quarter. Institutional investors own 95.70% of the company's stock.

DENTSPLY SIRONA Trading Up 0.4%

NASDAQ:XRAY opened at $11.17 on Tuesday. The company's 50 day moving average price is $12.12 and its 200-day moving average price is $11.71. The company has a quick ratio of 1.07, a current ratio of 1.63 and a debt-to-equity ratio of 1.48. DENTSPLY SIRONA Inc. has a 52 week low of $9.40 and a 52 week high of $14.86. The stock has a market cap of $2.23 billion, a price-to-earnings ratio of -4.06, a PEG ratio of 1.42 and a beta of 0.85.

DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.35 by $0.17. DENTSPLY SIRONA had a positive return on equity of 20.84% and a negative net margin of 14.99%.The firm had revenue of $898.00 million during the quarter, compared to analysts' expectations of $889.93 million. During the same quarter in the previous year, the business earned $0.52 earnings per share. The company's revenue was down 4.1% on a year-over-year basis. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. On average, equities research analysts forecast that DENTSPLY SIRONA Inc. will post 1.4 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Brian P. Mckeon acquired 10,000 shares of the firm's stock in a transaction dated Friday, June 12th. The stock was purchased at an average cost of $10.12 per share, with a total value of $101,200.00. Following the completion of the acquisition, the director directly owned 10,000 shares of the company's stock, valued at approximately $101,200. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Michael J. Barber acquired 15,175 shares of the stock in a transaction that occurred on Thursday, June 11th. The shares were bought at an average price of $9.88 per share, for a total transaction of $149,929.00. Following the transaction, the director owned 55,943 shares of the company's stock, valued at $552,716.84. This trade represents a 37.22% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have purchased a total of 35,160 shares of company stock valued at $351,179 in the last 90 days. 0.46% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of research analysts recently issued reports on XRAY shares. Weiss Ratings reissued a "sell (e+)" rating on shares of DENTSPLY SIRONA in a research report on Monday, August 3rd. Mizuho cut their price objective on shares of DENTSPLY SIRONA from $16.00 to $14.00 and set a "neutral" rating on the stock in a report on Wednesday, May 6th. Barclays raised their target price on shares of DENTSPLY SIRONA from $9.00 to $11.00 and gave the company an "underweight" rating in a research note on Monday, August 24th. UBS Group dropped their price target on DENTSPLY SIRONA from $18.00 to $17.00 and set a "buy" rating on the stock in a research report on Thursday, May 7th. Finally, Piper Sandler upped their price target on DENTSPLY SIRONA from $13.00 to $14.00 and gave the stock a "neutral" rating in a research note on Wednesday, July 29th. Three research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have issued a Sell rating to the company's stock. According to data from MarketBeat, DENTSPLY SIRONA currently has an average rating of "Hold" and an average target price of $13.54.

DENTSPLY SIRONA Profile

Dentsply Sirona Inc NASDAQ: XRAY is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company's product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.

Want to see what other hedge funds are holding XRAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.